The Food and Drug Administration announced on Friday it officially declared the end of the nation Shortage of Ozempic and Wegovymedications used for diabetes and weight loss.
The agency first declared a shortage of Semaglutide, the main ingredient used to make Ozempic and Wegovy in 2022.
The FDA’s announcement comes months after drug maker Novo Nordisk told the agency that all doses of its semaglutide products are now fully available nationwide. The company said in a statement To see the supply of drugs, which are prescription-only, “meets or exceeds both current and projected demand.”
“This update comes after a continuous dialogue with the FDA, and will be a substantial effort from Novo Nordisk to increase manufacturing capacity, including a $6.5 billion investment in the US this year alone,” Drug The manufacturer said.
The FDA said it will allow compounding pharmacies to continue making copies of semaglutide for now.
That leeway will continue to be continued at many pharmacies until April 22 and until May 22 to outsource facilities to “avoid unnecessary confusion” to patients, the agency said.
This is similar to what the FDA grants to a combined pharmacy that makes copies Eli Lily’s diabetes and weight loss drug tilzepatide, Ongoing lawsuits It was brought about by an outsourcing facility that challenges the FDA’s decision to declare a shortage of its weight loss drugs.
Several combined pharmacies and outsourcing facilities have created millions Copying semaglutide and tilzepatide During their shortages in recent years, amidst the gusts of businesses cashing in response to drug demands.
The FDA is also facing calls to do more to crack down on Drug counterfeitingincluding the state attorney general. I was urged This week, the agency will suspend illegal imports from overseas.
“Demand for Mounjaro, Zepbound, Ozempic and Wegovy (GLP-1 Drugs) has skyrocketed, but the supply shortage and high costs have created opportunities for fraudsters to cash out and put consumers at risk.” They write.
